公开(公告)号：EP2379063A1

公开(公告)日：2011-10-26

申请号：EP10700730.4

申请日：2010-01-08

Applicant: Forward Pharma A/S

Inventor： NILSSON, Henrik ,  RUPP, Roland

IPC: A61K9/28 ,  A61K31/215 ,  A61P17/06

CPC classification number: A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

公开(公告)号：US20170014367A2

公开(公告)日：2017-01-19

申请号：US14209480

申请日：2014-03-13

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Bernd MUELLER

IPC: A61K31/225 ,  A61K9/48 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract translation: 本发明涉及包含富马酸酯作为活性物质的控释药物组合物。 该组合物适合用于治疗例如儿童。 牛皮癣或其他过度增生，炎性或自身免疫性疾病，并被指定以受控的方式释放富马酸酯，使得可以避免在口服给药时在胃肠道内的局部高浓度的活性物质，从而能够减少胃 - 肠道相关副作用。

公开(公告)号：US20160271093A2

公开(公告)日：2016-09-22

申请号：US14209480

申请日：2014-03-13

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Bernd W. MUELLER

IPC: A61K31/225 ,  A61K9/48 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：US20140200273A1

公开(公告)日：2014-07-17

申请号：US14209651

申请日：2014-03-13

Applicant: FORWARD PHARMA A/S

Inventor： Henrik NILSSON ,  Florian SCHOENHARTING ,  Bernd W. MUELLER ,  Joseph R. ROBINSON

IPC: A61K31/225

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：US20130316003A1

公开(公告)日：2013-11-28

申请号：US13957220

申请日：2013-08-01

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian SCHÖNHARTING ,  Bernd W. MÜLLER ,  Joseph R. ROBINSON

IPC: A61K31/225

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention features a method of treating a subject in need of treatment for multiple sclerosis. The method involves orally administering to the subject in need thereof a pharmaceutical composition in unit dosage form consisting essentially of (a) from about 120 mg to about 240 mg of dimethylfumarate formulated for delayed release, and (b) one or more pharmaceutically acceptable excipients, wherein following the orally administering of the unit dosage form monomethylfumarate appears in the plasma of the subject upon hydrolysis of dimethylfumarate and the Cmax of the monomethylfumarate in the plasma of the subject is between about 0.4 and about 2 mg/L, and wherein about 480 mg of dimethylfumarate per day is orally administered to the subject.

Abstract translation: 本发明的特征在于治疗需要治疗多发性硬化症的受试者的方法。 该方法包括向有需要的受试者口服施用基本上由（a）约120mg至约240mg配制用于延迟释放的富马酸二甲酯组成的单位剂型的药物组合物，和（b）一种或多种药学上可接受的赋形剂， 其中，口服单次剂量形式的富马酸单甲酯在水解富马酸二甲酯时出现在受试者的血浆中，受试者血浆中富马酸一甲酯的C max为约0.4至约2mg / L，其中约480mg 每日口服给予受试者的富马酸二甲酯。

公开(公告)号：EP2801354B1

公开(公告)日：2017-02-08

申请号：EP14172390.8

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd, W. ,  Robinson, Joseph, R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP3038606A1

公开(公告)日：2016-07-06

申请号：EP14755818.3

申请日：2014-08-26

Applicant: Forward Pharma A/S

Inventor： GALETZKA, Christin ,  RUNDFELDT, Chris ,  RUPP, Roland ,  ANDERSEN, Peder M.

IPC: A61K9/28 ,  A61K31/225

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K9/2846

Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

Abstract translation: 本发明涉及含有富马酸二甲酯（DMF）的药物组合物，更具体地说，本发明涉及口服用于治疗过度增殖性，炎性或自身免疫性疾病的药物组合物，其通过施用410mg±5 ％或400mg±5％富马酸二甲酯，其中所述药物制剂为侵蚀骨架片剂形式。

公开(公告)号：EP2801355B1

公开(公告)日：2015-05-20

申请号：EP14172398.1

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd, W. ,  Robinson, Joseph, R.

IPC: A61K9/20 ,  A61K9/50

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP2564839A3

公开(公告)日：2013-04-17

申请号：EP12193798.1

申请日：2010-01-08

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Rupp, Roland

IPC: A61K9/28 ,  A61K31/215 ,  A61P17/06 ,  A61K9/20 ,  A61K31/225

CPC classification number: A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

公开(公告)号：EP2316430B8

公开(公告)日：2012-07-11

申请号：EP10182198.1

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd W ,  Robinson, Joseph R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.